文献速递白血病造血干细胞移植与细胞治疗

供者来源多白血病抗原特异性T细胞疗法预防急性淋巴细胞白血病患者移植后复发

Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant in patients with ALL.
PubMed 文献 · Blood · 2022-01-01

研究制备并输注靶向PRAME、WT1和survivin的供者来源多白血病抗原特异性T细胞(mLSTs),用于11例急性淋巴细胞白血病(ALL)患者(8例儿童、3例成人),剂量范围为0.5×10^7至2×10^7个细胞/平方米。未观察到剂量限制性毒性、急性移植物抗宿主病或细胞因子释放综合征;8例可评估患者中6例保持长期完全缓解(中位46.5个月,范围9-51个月)。

要点

  • 输注供者来源mLSTs未观察到剂量限制性毒性、急性GVHD或细胞因子释放综合征。
  • 8例可评估患者中6例保持长期完全缓解,中位46.5个月(范围9-51个月)。
  • 输注后短期内可检测到肿瘤反应性T细胞频率增加,提示体内抗原扩散。

核心结论

  • 异基因造血干细胞移植后输注供者来源mLSTs可行且安全,可能有助于疾病控制,表现为体内肿瘤导向T细胞扩增。
  • 该方法代表一种有前景的预防ALL患者复发策略。

研究设计与样本

  • 研究制备并输注靶向PRAME、WT1和survivin的供者来源多白血病抗原特异性T细胞(mLSTs)。
  • mLSTs输注剂量范围为0.5×10^7至2×10^7个细胞/平方米。
  • 共输注11例ALL患者(8例儿童、3例成人)。

主要发现

  • 未观察到剂量限制性毒性、急性移植物抗宿主病或细胞因子释放综合征。
  • 8例可评估患者中6例保持长期完全缓解(中位46.5个月;范围9-51个月)。
  • 在上述个体中,输注后短期内检测到肿瘤反应性T细胞频率增加,对靶向和非靶向的已知肿瘤相关抗原均有活性,提示体内抗原扩散。
  • 2例复发患者中未观察到这种体内扩增。

临床怎么用

  • 异基因造血干细胞移植后输注供者来源mLSTs可行且安全,可能有助于疾病控制。
  • 作者认为该方法代表一种有前景的预防ALL患者复发策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hematopoietic stem cell transplant (HSCT) is a curative option for patients with high-risk acute lymphoblastic leukemia (ALL), but relapse remains a major cause of treatment failure. To prevent disease relapse, we prepared and infused donor-derived multiple leukemia antigen-specific T cells (mLSTs) targeting PRAME, WT1, and survivin, which are leukemia-associated antigens frequently expressed in B- and T-ALL. Our goal was to maximize the graft-versus-leukemia effect while minimizing the risk of graft-versus-host disease (GVHD). We administered mLSTs (dose range, 0.5 × 107 to 2 × 107 cells per square meter) to 11 patients with ALL (8 pediatric, 3 adult), and observed no dose-limiting toxicity, acute GVHD or cytokine release syndrome. Six of 8 evaluable patients remained in long-term complete remission (median: 46.5 months; range, 9-51). In these individuals we detected an increased frequency of tumor-reactive T cells shortly after infusion, with activity against both targeted and nontargeted, known tumor-associated antigens, indicative of in vivo antigen spreading. By contrast, this in vivo amplification was absent in the 2 patients who experienced relapse. In summary, infusion of donor-derived mLSTs after allogeneic HSCT is feasible and safe and may contribute to disease control, as evidenced by in vivo tumor-directed T-cell expansion. Thus, this approach represents a promising strategy for preventing relapse in patients with ALL.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Naik S, Vasileiou S, Tzannou I, et al. Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant in patients with ALL. Blood. 2022. PMID: 35134127. doi:10.1182/blood.2021014648

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。